Du är här

2015-09-29

Swedish Orphan Biovitrum AB (publ): Sobi CEO invests in 2015 LTI programme and divests a portion of incentive shares

On 25 September Swedish Orphan Biovitrum AB (publ)'s (Sobi) CEO Geoffrey
McDonough purchased 34,000 Sobi shares as part of the company's 2015 CEO
long-term incentive programme. The programme requires that the CEO make an
investment in common shares in Sobi for an amount of 4 MSEK which are subject
to a 3 year lock-up period.

Geoffrey McDonough also divested 78,500 of the shares he holds in Sobi. The
sale was made in order to cover the estimated US tax due for the company's
2012 long-term incentive programme which vested in June 2015. The CEO now
holds a total of 774,923 shares in the company.

---

Terms and conditions of the Sobi 2015 CEO long-term incentive program can be
found onwww.sobi.com.

About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of specialty and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on
NASDAQ OMX Stockholm. More information is available atwww.sobi.com.

For more information please contact

----------------------------------------------------------------------------------------------------
| Media relations Investor relations |
| Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations |
| T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
| oskar.bosson@sobi.com jorgen.winroth@sobi.com |
----------------------------------------------------------------------------------------------------

036e_CEO shares
http://hugin.info/134557/R/1955029/711651.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire

HUG#1955029

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.